Hepatitis C Virus: No Longer a Barrier to Oncology Care.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30676362.
- Also identified by DOI 10.14309/ajg.0000000000000095.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Historically, hepatitis C virus infection has posed a barrier to cancer therapies and enrollment in clinical trials for oncology patients. Oral direct acting antivirals now allow most patients, previously considered difficult to treat to be effectively (>95% sustained virologic response) and safely cured.
Medical subject headings
- Antiviral Agents
- Hepatitis C
- Hepatitis C, Chronic
- Neoplasms